News
Novo Nordisk Offers Ozempic at $499 Per Month to Eligible US Cash-Paying Customers
(Reuters) -Novo Nordisk said on Monday it was offering its diabetes drug Ozempic for $499 per month to eligible cash-paying patients with type 2 diabetes in the U.S. via its own pharmacy, a tie-up with telehealth service GoodRx and other platforms.
Green Matters on MSN10h
Ozempic Sparks Both Weight Loss Success Stories and Major Lawsuits in 2025
The weight loss injectable Ozempic has faced several lawsuits in 2025 from people who had a negative experience with the ...
Ozempic faces over 1,800 lawsuits in US courts, with damages possibly topping $2 billion. Patients allege the drug caused ...
GoodRx and Novo Nordisk launch a $499 monthly self-pay option for Ozempic and Wegovy, expanding access at 70,000 pharmacies across the U.S.
The maker of Ozempic is halving the price of its weight-loss jabs in the US after Donald Trump demanded cheaper drugs for ...
New studies link Ozempic and Wegovy to rare vision loss, but experts say the risk is quite small. Here’s what you need to ...
But now, women have complained of 'Ozempic vulva' and its side effects. One woman on Reddit complained of 'pain when biking ...
The pioneering Danish drugmaker was once the most valuable company in Europe, but analysts say a number of missteps reversed ...
With a new endorsement from the FDA, Novo Nordisk’s Wegovy has picked up its third indication and become the second drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback